Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treating head and neck cancer—A multidisciplinary effort

Treating head and neck cancer—A multidisciplinary effort editorial memo (2020) 13:359–360 https://doi.org/10.1007/s12254-020-00656-3 Gabriele Gamerith · Thorsten Fuereder © Springer-Verlag GmbH Austria, part of Springer Nature 2020 Head and neck (HNC) is the tenth most common can- For tumors, however, which are located near the cer worldwide with over 650,000 new cases per year skull base or in a previously irradiated field, particle [1–3]. The major risk factors for development of squa- therapy employing protons can provide a novel treat- mous cell HNC comprise alcohol and tobacco con- ment option accompanied with reduced side effects sumption [4]. During the last few decades human compared to conventional photon therapy. In addi- papilloma virus (HPV) infection has been identified tion to protons, carbon ions recently entered the stage to contribute to the development of oropharyngeal providing benefits for the treatment of radioresistant HNC in a younger subgroup of patients [5]. This histologies such as adenoid cystic carcinomas. population shows a more favorable prognosis com- Despite the improvements outlined above, recur- pared to HPV-negative disease [5]. Standard treatment rence rates of stage III/IV disease after curative ther- options for HNC independent of HPV status include apy is about 50% in the first 2 years of follow-up [6, 7]. surgery, standard http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Treating head and neck cancer—A multidisciplinary effort

Loading next page...
 
/lp/springer-journals/treating-head-and-neck-cancer-a-multidisciplinary-effort-bOO02R8nKV
Publisher
Springer Journals
Copyright
2020 Springer-Verlag GmbH Austria, part of Springer Nature
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-020-00656-3
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2020) 13:359–360 https://doi.org/10.1007/s12254-020-00656-3 Gabriele Gamerith · Thorsten Fuereder © Springer-Verlag GmbH Austria, part of Springer Nature 2020 Head and neck (HNC) is the tenth most common can- For tumors, however, which are located near the cer worldwide with over 650,000 new cases per year skull base or in a previously irradiated field, particle [1–3]. The major risk factors for development of squa- therapy employing protons can provide a novel treat- mous cell HNC comprise alcohol and tobacco con- ment option accompanied with reduced side effects sumption [4]. During the last few decades human compared to conventional photon therapy. In addi- papilloma virus (HPV) infection has been identified tion to protons, carbon ions recently entered the stage to contribute to the development of oropharyngeal providing benefits for the treatment of radioresistant HNC in a younger subgroup of patients [5]. This histologies such as adenoid cystic carcinomas. population shows a more favorable prognosis com- Despite the improvements outlined above, recur- pared to HPV-negative disease [5]. Standard treatment rence rates of stage III/IV disease after curative ther- options for HNC independent of HPV status include apy is about 50% in the first 2 years of follow-up [6, 7]. surgery, standard

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Dec 1, 2020

Keywords: oncology; medicine/public health, general

References